NASDAQ:HOWL Werewolf Therapeutics Q2 2024 Earnings Report $0.52 0.00 (0.00%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$0.52 +0.01 (+1.92%) As of 07:56 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Werewolf Therapeutics EPS ResultsActual EPS-$0.43Consensus EPS -$0.38Beat/MissMissed by -$0.05One Year Ago EPSN/AWerewolf Therapeutics Revenue ResultsActual Revenue$1.14 millionExpected Revenue$2.00 millionBeat/MissMissed by -$860.00 thousandYoY Revenue GrowthN/AWerewolf Therapeutics Announcement DetailsQuarterQ2 2024Date8/8/2024TimeN/AConference Call DateThursday, August 8, 2024Conference Call Time11:00AM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Werewolf Therapeutics Earnings HeadlinesHere's Why We're A Bit Worried About Werewolf Therapeutics' (NASDAQ:HOWL) Cash Burn SituationMay 14, 2026 | finance.yahoo.comWerewolf Therapeutics (NASDAQ:HOWL) Rating Lowered to Sell at Wall Street ZenMay 9, 2026 | americanbankingnews.comSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a $1.75 trillion IPO - larger than Saudi Aramco and any tech offering in history. CNBC calls it 'the big market event of 2026.' According to former tech executive and angel investor Jeff Brown, there's a way to claim a stake before the public filing drops, starting with as little as $500.May 18 at 1:00 AM | Brownstone Research (Ad)Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Receives Consensus Rating of "Hold" from AnalystsMay 8, 2026 | americanbankingnews.comWerewolf Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate UpdatesMay 7, 2026 | globenewswire.comWerewolf Therapeutics (HOWL) price target increased by 12.00% to 7.14April 28, 2026 | msn.comSee More Werewolf Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Werewolf Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Werewolf Therapeutics and other key companies, straight to your email. Email Address About Werewolf TherapeuticsWerewolf Therapeutics (NASDAQ:HOWL) (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity. Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs. These investigational agents are engineered to engage key immune pathways—such as T-cell activation and pro-inflammatory cytokine signaling—only when proteolytically processed by enzymes present in the tumor milieu. This approach is intended to drive a potent, localized immune response against cancer cells while reducing the risk of adverse events associated with systemic cytokine exposure. The company’s pipeline spans both preclinical and early clinical stages, with lead programs targeting interleukin and tumor-necrosis factor family members. In addition to internal research efforts, Werewolf Therapeutics collaborates with academic institutions and industry partners to explore combination regimens that may further enhance the anti-tumor activity of its conditional agents. Founded in 2019 and headquartered in Cambridge, Massachusetts, Werewolf Therapeutics is led by a management team with extensive experience in immuno-oncology drug discovery and clinical development. The company is focused on advancing its pipeline through regulatory milestones and clinical proof-of-concept studies in the United States.View Werewolf Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Peloton Stock Gives Back Gains After Upbeat Earnings ReportDatavalut Gains Traction: 5 Reasons to Sell NowTMC Stock: Why This Pre-Revenue Miner Is Worth WatchingRobinhood, SoFi, and Webull Are Telling Very Different StoriesViking Sails to All-Time Highs—Fundamentals Signal More to ComeYETI Rallies After Earnings Beat and Raised OutlookAeluma's Post-Earnings Dip Creates a Buying Opportunity Upcoming Earnings Palo Alto Networks (5/19/2026)Home Depot (5/19/2026)Keysight Technologies (5/19/2026)Analog Devices (5/20/2026)Intuit (5/20/2026)NVIDIA (5/20/2026)Lowe's Companies (5/20/2026)Medtronic (5/20/2026)Target (5/20/2026)TJX Companies (5/20/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
